HAE Quote, Financials, Valuation and Earnings

Bruker has a net margin of 10.76% compared to Haemonetics's net margin of 1.4%. Haemonetics's return on equity of 14.16% beat Bruker's return on equity of 6.78%.

Haemonetics has a consensus price target of $96.30, signalling upside risk potential of 57.79%. On the other hand Bruker has an analysts' consensus of $63.98 which suggests that it could grow by 55.32%. Given that Haemonetics has higher upside potential than Bruker, analysts believe Haemonetics is more attractive than Bruker.

Haemonetics has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.49% to investors and pays a quarterly dividend of $0.05 per share. Haemonetics pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics quarterly revenues are $348.5M, which are smaller than Bruker quarterly revenues of $979.6M. Haemonetics's net income of $37.5M is higher than Bruker's net income of $13.7M. Notably, Haemonetics's price-to-earnings ratio is 24.03x while Bruker's PE ratio is 54.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.28x versus 1.83x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 10.76% compared to Haemonetics's net margin of 12.41%. Haemonetics's return on equity of 14.16% beat Boston Scientific's return on equity of 8.96%.

Haemonetics has a consensus price target of $96.30, signalling upside risk potential of 57.79%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 19.22%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

Haemonetics has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Haemonetics's net income of $37.5M is lower than Boston Scientific's net income of $566M. Notably, Haemonetics's price-to-earnings ratio is 24.03x while Boston Scientific's PE ratio is 77.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.28x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 10.76% compared to Haemonetics's net margin of 4.03%. Haemonetics's return on equity of 14.16% beat Globus Medical's return on equity of 2.56%.

Haemonetics has a consensus price target of $96.30, signalling upside risk potential of 57.79%. On the other hand Globus Medical has an analysts' consensus of $98.08 which suggests that it could grow by 32.04%. Given that Haemonetics has higher upside potential than Globus Medical, analysts believe Haemonetics is more attractive than Globus Medical.

Haemonetics has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.425%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Globus Medical quarterly revenues of $657.3M. Haemonetics's net income of $37.5M is higher than Globus Medical's net income of $26.5M. Notably, Haemonetics's price-to-earnings ratio is 24.03x while Globus Medical's PE ratio is 99.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.28x versus 4.05x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems has a net margin of 10.76% compared to Haemonetics's net margin of 14.69%. Haemonetics's return on equity of 14.16% beat Inspire Medical Systems's return on equity of 8.4%.

Haemonetics has a consensus price target of $96.30, signalling upside risk potential of 57.79%. On the other hand Inspire Medical Systems has an analysts' consensus of $232.93 which suggests that it could grow by 51.44%. Given that Haemonetics has higher upside potential than Inspire Medical Systems, analysts believe Haemonetics is more attractive than Inspire Medical Systems.

Haemonetics has a beta of 0.409, which suggesting that the stock is 59.063% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.390, suggesting its more volatile than the S&P 500 by 38.99%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are larger than Inspire Medical Systems quarterly revenues of $239.7M. Haemonetics's net income of $37.5M is higher than Inspire Medical Systems's net income of $35.2M. Notably, Haemonetics's price-to-earnings ratio is 24.03x while Inspire Medical Systems's PE ratio is 88.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.28x versus 5.80x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.